About this policy
CMS evidence review | evidence_type=Technology Assessment | record_type=technology_assessment | document_id=30 | year=2005
Coverage indications
Age-related macular degeneration (AMD) is the leading cause of legal blindness in Americans over the age of 65. The cause of AMD it is thought to be related to multiple factors, and there is no cure for the disease. There are two basic types of AMD: dry and wet. Dry AMD is the most common type, accounting for 90% of all cases. Wet AMD accounts for 10% of cases and poses a higher risk of severe vision loss. There is no definitive treatment for dry AMD. For patients with wet AMD, several treatments are available.
Documentation requirements
Associated Medcac: MEDCAC Meeting for Age-related Macular Degeneration - 11/29/2005 Issue: Age-related macular degeneration (AMD) is the leading cause of legal blindness in Americans over the age of 65. The cause of AMD it is thought to be related to multiple factors, and there is no cure for the disease. There are two basic types of AMD: dry and wet. Dry AMD is the most common type, accounting for 90% of all cases. Wet AMD accounts for 10% of cases and poses a higher risk of severe vision loss. There is no definitive treatment for dry AMD. For patients with wet AMD, several treatments are available. Other Material: Other Material 1 Questions: Questions Technology Assessment: Download Technology Assessment [PDF, 1MB].
Codes in this policy
Code numbers and each code’s status as the policy records it. CPT code descriptions are left out of this page, as are the passages that cite CPT codes; the official document has them.
Backwork has no codes on record for this policy. Check the source.